However, the leading asexual blood-stage and liver-stage recombinant protein subunit vaccines candidates against malaria (MSP1, AMA1 and LSA1) have all failed in recent phase 2a experimental challenge studies and phase 2b field trials [4] despite induction of high antibody titre, growth inhibitory activity, and CD4+ T cell responses. Here, CD4 is linked to malaria.